Clinical Trial Update: Derazantinib and Atezolizumab in Patients With Urothelial Cancer [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating derazantinib with atezolizumab in urothelial carcinoma has been completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Urothelial Carcinoma

Drugs mentioned

• Atezolizumab (atezolizumab)
• Derazantinib (derazantinib)

Snippet

Sponsor: Basilea Pharmaceutica | Conditions: Urothelial Carcinoma | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2023-10-13